Skip to content

Assembly Biosciences ASMB Proceeds From Warrant Exercises

Proceeds From Warrant Exercises at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$0-100%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$53.54M

Other financials

Income statement

See full
Revenue$8.2M-12.8%
Operating income-$11.4M-14.4%
Net income-$9.1M-3.0%
EPS (diluted)-$0.54+53.8%

Balance sheet

See full
Cash & equivalents$31.1M+32.9%
Total debt$2.5M-17.5%
Total equity$198.6M+632%
Total assets$235.5M+138%

Cash flow

See full
Operating cash flow-$22.1M+5.7%
CapEx$19.0K
Free cash flow-$22.1M+5.6%

Valuation

See full
Market cap$480.77M+262%
Enterprise value$452.14M+302%
P/S6.8×+2.6×

Profitability

See full
Operating margin-116.8%-26.1pp
Net margin-103.6%-22.7pp
FCF margin-150%-231pp

Returns & leverage

See full
Return on equity-36.9%-15.1pp
Debt / equity-0.1×
Current ratio6.6×+4.6×

Where this comes from

Reported directly by Assembly Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: Assembly Biosciences’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Assembly Biosciences's proceeds from warrant exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Assembly Biosciences's proceeds from warrant exercises?
Assembly Biosciences (ASMB) reported proceeds from warrant exercises of $1.38M in Q4 2025.
What does proceeds from warrant exercises mean?
This represents the cash inflows resulting from the exercise of outstanding warrants by holders to purchase common stock at a predetermined price. It indicates that the company's stock price has reached levels that make warrant exercise attractive to investors. This provides a non-dilutive-like source of capital that strengthens the balance sheet.